Stop the Heparin Thromboprophylaxis
With an INR of 2.0, the patient has achieved therapeutic anticoagulation from warfarin, and continuing prophylactic-dose unfractionated heparin (UFH) 2500 IU twice daily is unnecessary and increases bleeding risk without additional benefit.
Rationale for Discontinuation
The fundamental principle in warfarin-heparin bridging is that heparin provides temporary anticoagulation only until warfarin achieves its therapeutic effect. Once the INR reaches the therapeutic range (typically 2.0-3.0 for most indications), the heparin should be discontinued 1, 2.
Key guideline recommendations:
ACC/AHA guidelines explicitly state that heparin should be started when INR falls below 2.0 during warfarin interruption, and conversely, should be discontinued when the desired INR is achieved 1
FDA warfarin labeling specifies that when converting from heparin to warfarin, "full dose heparin therapy should be overlapped with warfarin for 4 to 5 days, until warfarin has produced the desired therapeutic response as determined by PT/INR. When warfarin has produced the desired PT/INR or prothrombin activity, heparin may be discontinued" 2
European perioperative guidelines recommend that bridging heparin (whether UFH or LMWH) should be continued "until the INR has returned to therapeutic levels," implying discontinuation once therapeutic 3
Why Prophylactic Heparin is Inappropriate Here
The dose you mention (2500 IU twice daily) is a prophylactic dose, not a therapeutic bridging dose. This creates additional concerns:
Prophylactic UFH (typically 5000 IU BID or TID) is used for VTE prevention in hospitalized patients without established therapeutic anticoagulation 4
Therapeutic bridging requires much higher doses (typically 15,000 IU every 12 hours subcutaneously or continuous IV infusion) 1, 5
At 2500 IU BID, this dose provides neither adequate bridging anticoagulation nor is it necessary for prophylaxis when the patient already has an INR of 2.0
Clinical Decision Algorithm
If INR ≥ 2.0 on warfarin:
- Discontinue all heparin (prophylactic or therapeutic)
- Continue warfarin at maintenance dose
- Monitor INR per standard protocols (initially more frequently, then every 1-4 weeks once stable) 6, 2
If INR < 2.0 and patient requires therapeutic anticoagulation:
- Continue or initiate therapeutic-dose heparin (not prophylactic dose)
- For high-risk patients (mechanical heart valves, recent VTE, multiple risk factors): use therapeutic UFH or LMWH until INR ≥ 2.0 for at least 24-48 hours 1, 5
Common Pitfall to Avoid
Do not continue heparin "just to be safe" once INR is therapeutic. This practice:
- Increases bleeding risk without reducing thrombotic risk 7
- Represents unnecessary medication exposure and cost
- Can artificially elevate the aPTT, creating monitoring confusion 2
The warfarin FDA label specifically notes that "warfarin may increase the activated partial thromboplastin time (aPTT) test, even in the absence of heparin" 2, so continuing heparin when INR is therapeutic serves no purpose and complicates laboratory interpretation.